site logo

JPM22: Aftershocks for Lilly, CRISPR versus CRISPR and Bluebird's crucial year

A restrictive Medicare decision sent Lilly shares tumbling, while the CEO of Editas brushed off competitive threats.

Danielle Ternes / BioPharma Dive